The FDA on December 16, 2019 approved XTANDI® for patients with metastatic Castration-Sensitive Prostate Cancer (mCSPC). XTANDI® is a product of Astellas Pharma Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement